Acumen Pharmaceuticals Inc Stock News

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Business Officer James Doherty - President & Chief Development Officer Presentation Unknown Analyst All right. Here we go.

NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Alex Braun - VP & Head of Investor Relations Daniel J. O'Connell - CEO & Director Eric Siemers - Chief Medical Officer James Doherty - President & Chief Development Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Jason Eron Zemansky - BofA Se...

NEWTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2025 and provided a business update.

NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter 2025 financial results on Tuesday, August 12, 202...

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced a joint collaboration, option and license agreement with Acumen Pharmaceuticals to develop a novel therapeutic candidate for the treatment of Alzheimer's disease (AD), enabled by JCR's propriet...

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentatio...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and CBO Dr. Jim Doherty - President and CDO Dr. Eric Siemers - Chief Medical Officer Conference Call Participants Sarah Medeiros - Cantor Fitzgerald Tom Shrader ...